Abstract Objectives: This study aimed to investigate the prognostic value of lactate metabolism-related genes (LMRGs) in esophageal cancer (EC), exploring their roles in tumor microenvironment (TME) remodeling, immunotherapy response, and potential therapeutic targeting. Methods: Multi-omics analysis integrated bulk RNA-seq (TCGA, GEO) and single-cell RNA-seq (scRNA-seq) data. Differential expression, WGCNA, and LASSO regression were employed to identify prognostic LMRGs. Immune infiltration, drug sensitivity (GDSC), and pathway enrichment (GSEA/GSVA) analyses were performed. scRNA-seq delineated lactate-high cell populations in TME. Results: A 9-gene LMRG signature (ABRACL, CXCL8, TRIB3, DNMT3B, PHYHD1, KIF4A, CDKN3, LMNB2, PCLAF) was established, stratifying EC patients into high/low-risk groups with distinct survival (pConclusion: The LMRG model elucidates lactate-driven EC progression and immune evasion, offering prognostic biomarkers and therapeutic targets. Combining lactate modulation with targeted therapy may overcome treatment resistance.
Bai et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: